Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
Takabayashi K et al. | Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. | 1989 | Clin. Immunol. Immunopathol. | pmid:2466594 |
Morris RE et al. | Immunopharmacology of FK-506. | 1989 | Transplant. Proc. | pmid:2468201 |
Yoshimura N et al. | A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. | 1989 | Transplant. Proc. | pmid:2468202 |
Thomson AW et al. | Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. | 1989 | Transplant. Proc. | pmid:2468203 |
Sanghvi A et al. | Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. | 1989 | Transplant. Proc. | pmid:2468204 |
Takagishi K et al. | Effects of FK-506 on collagen arthritis in mice. | 1989 | Transplant. Proc. | pmid:2468205 |
Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
Siekierka JJ et al. | FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. | 1989 | J. Immunol. | pmid:2474605 |
Thomson AW and Woo J | Immunosuppressive properties of FK-506 and rapamycin. | 1989 | Lancet | pmid:2474733 |
Todo S et al. | Renal transplantation in baboons under FK 506. | 1989 | Surgery | pmid:2474865 |
Kay JE et al. | Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. | 1989 | Immunology | pmid:2475433 |
Moriyama S | [Experimental tracheal reconstruction by allotransplantation]. | 1989 | Nihon Kyobu Geka Gakkai Zasshi | pmid:2475555 |
Freedman RB | Immunosuppression. Convergence of drug action. | 1989 | Nature | pmid:2477712 |
Siekierka JJ et al. | A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. | 1989 | Nature | pmid:2477714 |
McCauley J et al. | Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. | 1989 Dec 23-30 | Lancet | pmid:2481200 |
Collier SJ | Immunosuppressive drugs. | 1989-1990 | Curr. Opin. Immunol. | pmid:2484794 |
Thomson AW | Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. | 1990 | Transplant. Proc. | pmid:1689883 |
Zeevi A et al. | Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689884 |
Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
McCauley J et al. | The effects of FK 506 on renal function after liver transplantation. | 1990 | Transplant. Proc. | pmid:1689887 |
Kang Y et al. | Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. | 1990 | Transplant. Proc. | pmid:1689889 |
Jain AB et al. | FK 506 dosage in human organ transplantation. | 1990 | Transplant. Proc. | pmid:1689890 |
McCauley J et al. | FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. | 1990 | Lancet | pmid:1690326 |
Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
Morimoto T et al. | Pancreaticoduodenal allotransplantation with FK 506 in the dog. | 1990 | Transplant. Proc. | pmid:1691550 |
Yasunami Y et al. | Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. | 1990 | Transplant. Proc. | pmid:1691557 |
Iga C et al. | Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. | 1990 | Transplant. Proc. | pmid:1697118 |
Deguchi K et al. | [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. | 1990 | No To Shinkei | pmid:1697182 |
Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia. | 1990 | Life Sci. | pmid:1698241 |
Kurasawa K et al. | The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. | 1990 | Clin. Immunol. Immunopathol. | pmid:1698584 |
Miyagawa J et al. | Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. | 1990 | Diabetologia | pmid:1698679 |
Suzuki S et al. | In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. | 1990 | Heart Vessels | pmid:1699922 |
Bierer BE et al. | Probing immunosuppressant action with a nonnatural immunophilin ligand. | 1990 | Science | pmid:1700475 |
Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
Wicker LS et al. | Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. | 1990 | Eur. J. Immunol. | pmid:1700753 |
Sigal NH et al. | Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. | 1990 | Biochem. Pharmacol. | pmid:1700909 |
Hara S et al. | The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. | 1990 | Clin. Immunol. Immunopathol. | pmid:1700936 |
Murase N et al. | Effect of FK 506 on spontaneous diabetes in BB rats. | 1990 | Diabetes | pmid:1700959 |
Woo J et al. | Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. | 1990 | Immunology | pmid:1703987 |
Ni M et al. | FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. | 1990 | Autoimmunity | pmid:1717008 |